Results 251 to 260 of about 309,141 (294)
Some of the next articles are maybe not open access.
Regorafenib for metastatic colorectal cancer
The Lancet, 2013Comment in Regorafenib for metastatic colorectal cancer - Authors' reply. [Lancet. 2013]
Myung Han, Hyun +2 more
+8 more sources
Chemotherapy of metastatic colorectal cancer
Current Treatment Options in Gastroenterology, 2005Over the past decade, metastatic colorectal cancer has evolved from a relatively resistant disease to one that is sensitive to a variety of chemotherapeutic drugs and combinations of drugs. During the same period, the median survival of patients with metastatic colorectal cancer increased from approximately 14 months to almost 20 months.
Everardo D, Saad, Paulo M, Hoff
openaire +2 more sources
Metastatic colorectal cancer: Therapeutic options
Current Treatment Options in Oncology, 2006For the past several decades, the therapy for metastatic colorectal cancer had modest benefits because of the limited therapeutic options. Bolus 5-fluorouracil (5FU) and leucovorin (LV) were the standard of care in the United States until 2002, with a response rate of 25% and a median survival of 10 to 12 months. However, with the advent of new agents,
Smitha, Patiyil, Steven R, Alberts
openaire +2 more sources
Cetuximab in metastatic colorectal cancer
Expert Review of Anticancer Therapy, 2012Management of metastatic colorectal cancer has evolved in the last 10 years, with the availability of targeted therapies resulting in improvement in quality of life and overall survival. Cetuximab is a chimeric monoclonal antibody that binds to the EGF receptor, and the net effects are inhibition of tumor growth, invasion, angiogenesis and metastasis ...
Broadbridge, V. +2 more
openaire +3 more sources
Panitumumab in metastatic colorectal cancer
Expert Review of Anticancer Therapy, 2013Increasing chemotherapeutic and targeted drug options has led to improved overall survival in metastatic colorectal cancer. Panitumumab is a fully humanized monoclonal antibody that binds to the EGF receptor and inhibits downstream cell signaling with net effects of inhibition of tumor growth, induction of apoptosis and inhibition of angiogenesis ...
Hocking, C., Townsend, A., Price, T.
openaire +3 more sources
Chemotherapy in metastatic colorectal cancer
Surgical Oncology, 2007This article aims to provide the reader with a broad overview of the current chemotherapeutic options available for the treatment of patients with metastatic colorectal cancer. The review includes discussion of both well established and experimental therapies.
Claire, Kelly, Jim, Cassidy
openaire +2 more sources
Regorafenib in metastatic colorectal cancer
Expert Review of Anticancer Therapy, 2014Regorafenib is an oral multikinase inhibitor that blocks the activity of protein kinases involved in the regulation of tumor angiogenesis (VEGFR1, 2, 3; angiopoietin-1 receptor), oncogenesis (stem cell growth factor receptor; RET; BRAF including BRAFV600E), and tumor microenvironment (PDGFR-β and FGFR).
A. Sartore Bianchi +5 more
openaire +2 more sources
Treatment of Metastatic Colorectal Cancer
Seminars in Oncology, 2011The treatment of metastatic colorectal cancer (mCRC) has become increasingly complex and nuanced as treatments have evolved over the last decade. During that time, treatment has evolved from single agent 5-fluorouracil (5FU) chemotherapy to combination chemotherapy, and more recently to the inclusion of monoclonal antibodies.
Janine M, Davies, Richard M, Goldberg
openaire +2 more sources
Chemotherapy for Metastatic Colorectal Cancer
Journal of the National Comprehensive Cancer Network, 2005The past decade has seen a significant survival improvement for patients with metastatic colorectal cancer, fueled in large part by the arrival of active novel chemotherapeutic drugs and their incorporation into combination regimens. Several randomized trials have successfully integrated oxaliplatin and irinotecan into previously existing 5 ...
Joseph, Rosales, Lucille A, Leong
openaire +2 more sources
Chemotherapy for metastatic colorectal cancer
Drug and Therapeutics Bulletin, 2002Of the 30,000 people in the UK who develop colorectal cancer each year, around 70-80% undergo potentially curative surgery. Even so, around a half of all patients eventually die from metastatic disease,1 typically within 5 years of diagnosis. Many patients who develop metastases are offered systemic chemotherapy to try to extend survival and maintain ...
openaire +2 more sources